US vs UK Surgical Robotics: Where Hospitals Will Spend Next and Where Manufacturers Can Enter

US vs UK: What drives hospital investment? The strongest business opportunities are below the robot itself Entry strategy: How emerging manufacturers can compete What investors should evaluate before entering

Surgical robotics is no longer just a contest to build the most advanced robot. The commercial opportunity now includes affordable platforms, recurring instruments, specialised surgical applications, and software that helps hospitals improve utilisation.

In 2025, Intuitive Surgical reported approximately 3.153 million da Vinci procedures worldwide, an 18% increase year over year. In the UK, robotic-assisted procedures recorded by NHS trusts increased from 3,622 in 2014 to 36,209 in 2024. These figures show substantial growth, but the two datasets measure different geographies and periods.

Downlaod Top Company Quadrants with Master Dataset, Buyer Identification and More: https://www.towardshealthcare.com/download-sample/5502

US vs UK: What drives hospital investment?

Investment factor	United States	United Kingdom
Main purchasing drivers	Procedure volume, surgeon demand, hospital competition	Clinical evidence, affordability, NHS procurement
Commercial opportunity	Premium systems, consumables, service contracts	Cost-effective platforms, competitive alternatives, service support
Key barrier	High capital and ongoing operating costs	Budget constraints and evidence of value
Entry strategy	Private hospital partnerships and specialist distributors	NHS tenders, framework competitions and hospital pilots

The US is attractive for suppliers that can demonstrate strong utilisation and a clear financial case. The UK offers opportunities for manufacturers that can prove clinical value while meeting public-sector purchasing requirements.

The strongest business opportunities are below the robot itself

The UK adoption study recorded 212 robotic surgical systems across 100 NHS trusts in 2024. Intuitive platforms accounted for approximately 75% of the installed systems, while CMR Surgical's Versius accounted for 9%. This indicates an established competitor base, but also shows that alternative platforms have entered the sector.

For new entrants, the opportunity is to address specific gaps without attempting to replicate an entire premium system.

Market gap	Product opportunity	Initial target customers
High system acquisition costs	Leasing, usage-based pricing and lower-cost platforms	Hospitals evaluating their first robotic system
Recurring instrument expenditure	Cost-efficient instruments and accessories	High-volume surgical departments
Low utilisation of installed systems	Scheduling, utilisation and maintenance software	Hospitals with existing robotic programmes
Specialised procedure requirements	Procedure-specific robotic tools	Specialist surgical centres
Training and implementation barriers	Simulation, training and workflow support	Hospitals expanding robotic programmes

These are potential business opportunities, not proven unmet-demand estimates. Manufacturers should validate purchasing budgets, competing products, regulatory requirements, and hospital willingness to pay before investing.

Entry strategy: How emerging manufacturers can compete

Avoid launching with an expensive, full-scale robotic platform unless the company has substantial capital, engineering capabilities, clinical partnerships, and a credible regulatory pathway.

A more practical approach is to start with one measurable problem, validate it with hospitals, and expand after demonstrating commercial value.

Stage 1: Build a focused product. Start with workflow software, training technology, maintenance analytics, or independently developed surgical accessories.
Stage 2: Secure clinical partners. Work with surgeons and hospitals to validate usability, safety, and the problem being solved.
Stage 3: Prove economic value. Measure cost per procedure, utilisation, operating-room delays, or training time against a defined baseline.
Stage 4: Expand through partnerships. Approach established manufacturers, distributors, and hospital procurement teams with documented results.

In the UK, NHS England's guidance published on 1 September 2026 establishes further competition as the default route for new robotic surgery purchases under national frameworks. Suppliers should therefore prepare evidence-based bids, transparent pricing, and clear differentiation.

What investors should evaluate before entering

The most attractive opportunity is not necessarily the company with the most advanced robot. It may be the supplier that removes a cost, training, or utilisation barrier for hospitals.

Investors should assess five factors: the number of addressable hospitals, procedure volumes, competing products, recurring revenue potential, and the evidence required for regulatory approval and clinical adoption.

The key investment question is simple: Which product can make robotic surgery more accessible without compromising patient safety or clinical performance?

For manufacturers, investors, and healthcare organisations, a country-level assessment of surgical robot installations, competing platforms, procedure volumes, purchasing requirements, and product gaps can identify realistic entry points in the US and UK.

About Us

Healthcare WebWire is powered by Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium

About the Author

Payal Rabde

Principal Consultant

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.